Kornimate/medical-research-clean huggingface dataset:
assessment of balance in patients with pes planus

Conditions: Pes Planus; Fall Risk

Summary: introduction: pes planus is a foot deformity with increased contact of the foot with the ground as a result of the decrease or disappearance of the medial longitudinal arch of the foot. the arch of the foot creates an adaptive and flexible support for the whole body, and biomechanical changes in the foot can affect the whole body posture and balance. the results of the studies evaluating balance and plantar pressure analysis in adults with pes planus seem contradictory. the aim of this study is to evaluate fall risk and plantar pressure in adults with pes planus aged 50 -65 years

materials and methods: 34 cases with pes planus will be included in the study. medial longitudinal arch height of all cases will be evaluated by physical examination . affected foot, presence of "too many toes" sign will be observed. with the fingertip rise test, it will be checked whether the pes planus is flexible or rigid. inky foot analysis and plantar pressure analysis will be performed in cases. chippaux-smirak index and staheli arch index of all cases will be evaluated for the diagnosis of pes planus.the risk of falling will be calculated by evaluation of the balance with clinically and with posturography. results: statistical analyzes in the study will be made with the ncss (number cruncher statistical system) 2007 statistical software (utah, usa) package program. in addition to descriptive statistical methods (mean, standard deviation) in the evaluation of the data, the distribution of the variables will be examined with the shapiro - wilk normality test, one-way analysis of variance in the comparison of the normally distributed variables, tukey multiple comparison test in the comparison of subgroups, independent t test in the comparison of the paired groups, chi-square test will be used in comparisons of qualitative data. results will be evaluated at the level of significance p\<0.05. discussion: the results will be discussed according to the recent literature. in the literature, there are conflicting results about the balance and gait of adults with pes planus. in several studies in the literature, it has been found that the risk of falling is increased in elderly individuals with pes planus. the study can contribute to the literature in this perspective.

Eligibility criteria:
inclusion criteria: * patients aged 50 years and above with pes planus according to staheli arch index and chippaux- smirak index exclusion criteria: * congenital anomalies of the foot * prior lower extremity surgery inflammatory arthritis * neuromuscular diseases * diseases that interfere with lower extremity circulation * presence of orthostatic hypotension * untreated visual impairment * neurological and vestibular diseases * use of drugs that can cause balance disorders (antipsychotics, pregabalin, etc.)

Keywords: pes planus ink foot analysis pedobarography computed posturography
detection of salivary insulin following meals

Conditions: Insulin Resistance

Summary: in addition to its role as the major regulator of glucose uptake into peripheral tissues, the hormone insulin is also a primary regulator of fat storage and fat burning of the body. mechanistic animal studies have shown that high insulin may be the initial trigger for weight gain and be the proximal cause of obesity. there is currently no quick or non-invasive way of measuring insulin as research and clinical techniques require collection of a blood sample followed by a complicated and costly biochemical assay. the investigators will test the hypothesis that insulin levels can be accurately measured in saliva in humans following meals that elicit high and low blood insulin responses. findings will help determine if insulin can be use as a valid fluid to track insulin changes in humans.

lean and obese healthy participants will consume both a high carbohydrate meal and a low carbohydrate meal designed to elicit different insulin responses on two separate occasions. blood samples and saliva samples will be collected for 2 hours following each meal and insulin will be measured in both plasma and saliva. the relationship between plasma and saliva insulin following the two meals will be assessed.

Eligibility criteria:
inclusion criteria: * body mass index between 18.5-24.9 or over 30.0 kg/m2 exclusion criteria: * diabetes or other medical conditions affecting glucose or insulin levels * smoker * competitive athlete * vegan or vegetarian
expanding access to comprehensive geriatrics care via telehealth

Conditions: Geriatric Syndrome

Summary: the overall objective of the telegrace project is to improve the care and outcomes of older veterans with a recent inpatient stay by expanding access to the evidence-based grace program, by evaluating a telehealth implementation.

the telegrace evaluation will focus on three primary aims and a secondary aim: primary aim 1: to examine the effectiveness of the telegrace program, the investigators designed a randomized controlled implementation trial (rct) powered for the primary outcome of 90-day all-cause mortality. the investigators will also examine its effectiveness for the secondary outcomes including 90-day readmissions, 1-year ed utilization (va and non-va), 1-year all-cause readmissions, 1-year mortality, as well as patient, caregiver, and staff satisfaction. the investigators hypothesize that patients who receive telegrace will have lower 90-day mortality than patients in usual care. primary aim 2: to examine the implementation of the telegrace program. the implementation strategy is reflecting \& evaluating. implementation outcomes are based on the reaim framework and include reach, efficacy (aim 1), and implementation (total number of veterans served, fidelity). primary aim 3: to conduct a business-case analysis (bca). the business case analysis will calculate the net financial savings or loss for telegrace as the difference in the overall intervention costs and savings due to downstream benefits for patients receiving telegrace versus usual care controls.

Eligibility criteria:
inclusion criteria: * veterans discharged from the indianapolis va medical center (vamc) for an medical/surgical diagnosis (excludes substance use disorder-related admissions; excludes planned admissions) within the prior week * age 70 years * not enrolled in home-based primary care (hbpc) * not enrolled in hospice * not in dialysis * primary care visit within va in the prior 2 years * not residing in nursing home, skilled nursing facility, or clc. * living \>20 miles but \<60 miles from the indianapolis vamc facility * can score 95th percentile for mortality or missing can score * discharged from the hospital alive exclusion criteria: * patients who have been randomized to the control arm after their index hospitalization who become readmitted to the hospital may not be re-randomized. * by definition, grace patients are not eligible for telegrace due to the drive distance \>20 miles from the indianapolis vamc * enrolled in home-based primary care (hbpc) * enrolled in hospice * dialysis (hemodialysis or peritoneal dialysis) * residing in nursing home, skilled nursing facility, or clc. * living \<20 miles or 60 miles from the indianapolis vamc facility

Keywords: comprehensive geriatrics assessment telehealth home visit
rate of return to sport after total knee prosthesis: comparison of three types of prostheses

Conditions: Knee Arthropathy

Summary: the purpose of the study is the rate of return to sport (regardless of the sport envisaged) after a minimum of 3 years after total knee prosthesis.

this is an ambispective, comparative study of three cohorts, non-randomized, open, monocentric, relating to the return to sport of patients who have benefited from one of the three designs of prostheses under study (medial pivot, medial bearing and cruciate retaining) after total knee prosthesis. patients who received a total knee prosthesis with medial pivot, medial bearing and cruciate retaining prosthesis between 2018 and 2020 will be called by the investigator, and the study will be offered to them (d-3 to d0). the investigator will explain the study to the patient, send him the information note electronically and answer all his questions about the study. if the patient agrees to participate after a reflection period, the inclusion (d0) will be documented in the medical file, and the patient will be assessed the same day by telephone using the assessments set up in the study, except for the questionnaires on his functional and physical abilities that will be sent to him electronically. the patient will return his answers to the questionnaires on this same email address or by telephone according to his preference. a secure and unique email address will be created by the principal investigator for the purposes of the study and for use strictly specific to the study, in the investigating center.

Eligibility criteria:
inclusion criteria: * first total knee prosthesis between 2018 and 2020; * conventional alignment technique using the same surgical technique for total knee prosthesis; * placement of a medial pivot prosthesis (evolution®), mobile bearing (score® amplitude) or traditional cruciate retaining prosthesis (stryker® triathlon); * affiliation to a social security scheme; * patient having been informed and having given his oral non-objection exclusion criteria: * bilateral total knee prosthesis; * medical history of revision of total knee prosthesis; * articulation malformation of the lower limbs; * having undergone revision surgery; * inability to understand information related to the study for linguistic, psychological, cognitive reasons; * patient under legal protection, or deprived of liberty by judicial or administrative decision.
esmolol for the treatment of hypertension after intracerebral hemorrhage study (ethichs)

Conditions: Hemorrhagic Stroke

Summary: because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion. strategies that improve the blood pressure control of patients with hemorrhagic stroke during the first hours of hospitalization are determinant in controlling the hematoma expansion and determining factor in its prognosis. this study was designed with the objective of evaluating the beneficial effects of combining esmolol hydrochloride with sodium nitroprusside for the blood pressure control of participants with hemorrhagic stroke.

participants with parenchymal intracranial hemorrhage (diagnosis confirmed by computed tomography or magnetic resonance imaging), and: * with systolic pressure \> 150 mmhg, * not contraindicated for treatment with beta-blockers, * who can start the drug treatment within 6 hours of the stroke, * having a target of ≤ 140 mmhg of systolic pressure within 1 hour after initiation of treatment.

Eligibility criteria:
inclusion criteria: 1. signature of the tcle by participant or companion. 2. spontaneous intracerebral hemorrhage confirmed by computed tomography or magnetic resonance imaging and fit to be included in the study and initiate therapy with study medications within 6 hours after the event. 3. intracerebral hemorrhage (volume \< 30 cm3). 4. no immediate surgical indication. 5. both sexes, aged above 18 years. 6. systolic blood pressure (\> 150 mmhg and \< 220 mmhg) measured on two occasions with a minimum difference of 2 minutes. exclusion criteria: 1. cerebral hemorrhage secondary to structural lesions in the brain, vascular malformations, coagulopathies or traumatic brain injury, if known at the time of randomization. 2. participant in deep coma, defined by the glasgow coma scale score of 3 to 5. 3. uncontrolled asthmatic or copd participants, if known at the time of randomization. 4. participants with grade iv heart failure, defined as heart rate \< 50 beats per minute. 5. previous hemorrhagic stroke, if known at the time of randomization 6. participants with cerebral vascular stroke. 7. participants who have presented previous ischemic cerebrovascular accident, if known at the time of randomization. 8. chronic diseases with life expectancy less than 3 months. 9. score ≥ 4 on the ich score at the time of recruitment. 10. in use of anticoagulants in the last 48 hours, if known at the time of randomization. 11. patients with contraindication to any of the study medications. 12. intubation orotraqueal on arrival at the service. 13. pheochromocytoma, if known at the time of randomization. 14. patients with hyperthyroidism, if known at the time of randomization. 15. known pregnancy or breastfeeding . at the discretion of the investigator, an examination for confirmation may be requested.
elb139 given orally to patients with concurrent panic disorder, challenged by co2 inhalation after a single dose and one week of treatment

Conditions: Panic Disorder

Summary: this study is designed to investigate if 600 mg elb139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% co2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of concurrent panic disorder * at least 2 panic attacks within the 4 weeks before the screening visit * naïve to the co2 challenge test * age 18-65 years (inclusive) * ability to comply with all procedures mandated by the study protocol * negative pregnancy test and adequate contraceptive measures exclusion criteria: * history of poly-pharmacotherapy for panic disorder or treatment resistance * any current psychiatric axis i dsm-iv diagnosis other than panic disorder, except concurrent simple phobia * history of abuse of benzodiazepines or tolerance to effects of benzodiazepine * any concomitant psychotropic medication * evidence of impaired hepatic, renal or cardiac functions * participation in any drug trial in the preceding 6 months

Keywords: panic disorder proof of concept
comparison of method for skin closure in colorectal cancer.

Conditions: Surgical Site Infection; Colorectal Cancer

Summary: compared to tissue adhesives and skin stapling devices, tissue adhesives are reported to have advantages in terms of wound infection and cost competitiveness. however, there have been no prospective randomized studies focusing on wound infection rates and cost competitiveness between skin stapling devices and tissue adhesives in colorectal cancer surgery. in colon cancer surgery, it is still unclear which skin suturing method has advantages such as lower postoperative wound infection rate and price competitiveness. the purpose of this study is to compare clinical outcomes, including wound infection rates and cost-effectiveness, between two different wound closure methods for colorectal cancer.

the primary purpose of the study is to compare and analyze the incidence of surgical site infection within 30 days after surgery in each group when tissue adhesive was applied and when skin stapling device was applied. the purpose of the secondary study is to compare the clinical results after surgery by analyzing cost-effectiveness, pain level, and satisfaction after surgery between existing skin stapling and tissue adhesive for colon cancer patients. post-operative wound infection rate, cost (material costs of staplers, adhesives, material costs and service fees for disinfecting wounds occurring in the week after surgery), sex, age, bmi (body mass index), asa (anesthesiologists category), past history (diabetes, smoking history) , past abdominal surgery history), cancer stage, pre- and post-operative blood test results (wbc, crp), biopsy results (cancer type), surgery time, pain on the 1st and 3rd days after surgery (vas), length of stay, postoperative complications , compare the postoperative results of satisfaction.

Eligibility criteria:
inclusion criteria: * underwent elective colorectal surgery * aged 19 to 80 years * asa (american society of anesthesiologists) score: 1, 2 * surgical approach such as laparoscopic or robotic xi platform exclusion criteria: * asa score above 3 * aged over 80 years * underwent combined surgery for other organ resection * uncontrolled dm

Keywords: colorectal cancer skin adhesive bond skin stapling
a study of bgm0504 in poorly controlled type 2 diabetes patients only through diet and exercise

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: this is a multicenter, randomized, double-blind, placebo-controlled phase iii clinical study to evaluate the efficacy and safety of bgm0504 in patients with type 2 diabetes (t2d) with poor glycemic control only through diet and exercise. the main purpose is to evaluate the clinical efficacy of bgm0504 injection monotherapy for 32 weeks compared with placebo in chinese patients with type 2 diabetes with poor glycemic control only through diet and exercise, and to evaluate the clinical efficacy and safety of bgm0504 injection for 52 weeks of administration.


Eligibility criteria:
inclusion criteria: * ☑ have been diagnosed with type 2 diabetes mellitus (t2dm); * have a bmi ≥23 kilograms per meter squared (kg/m²) at screening; * be of stable weight (± 5%) for at least 3 months before screening; * have hba1c between ≥7.5% and ≤11.0%； * fasting plasma glucose (fpg) ≤ 15.0 mmol/l. exclusion criteria: * ■ previous diagnosis of type 1 diabetes, special type diabetes ; * there are malignant tumors within 5 years before screening, or patients are in latent of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery). * have had chronic or acute pancreatitis any time prior to study entry; * known allergic constitution (allergy to 3 or more kinds of food or drugs), or allergy to glp-1 receptor agonists, or severe allergic diseases (asthma, urticaria, eczematous dermatitis, etc.) at screening; * mentally incapacitated or speech-impaired; * suspected or confirmed history of alcohol or drug abuse; * pregnant or lactating woman; * the investigator considers that there are any other conditions that make it inappropriate to participate in this study.
molecular signatures of hpv+ orl cancers (oropap)

Conditions: Oropharyngeal Cancer; Human Papillomavirus-Related Carcinoma

Summary: the aim of this study is to identify hpv molecular signature in head and neck cancer to establish a new classification for positive human papillomavirus oropharyngeal tumor

oropap is a monocentric exploratory study with retrospective inclusion of patients. the retrospective study focus on patients who have had surgery for hpv-positive oropharyngeal tumors whose survival is at least 2 year. frozen and or ffpe biopsies of these tumors and frozen blood samples are available via the hegp biological resources platform. the hpv molecular signatures will be identified by the capture-hpv technique. for each patient, clinical-anatomo-pathological data such as tumor size, tumor stage, presence or absence of metastasis, histological stage, different treatment lines and 2-years survival data will be collected through the use of data warehouse available on the hegp.

Eligibility criteria:
inclusion criteria: * patients with hpv + oropharyngeal cancer exclusion criteria: * na

Keywords: orl cancers hpv+ tumor molecular signature human papillomavirus
the dynamic effect of non-cytochrome p450 isoenzyme 3a4（cyp3a4）-metabolized and cytochrome p450 isoenzyme 3a4（cyp3a4）-metabolized statins on clopidogrel resistance in patients with cerebral infarction

Conditions: Cerebral Infarction; Clopidogrel,Poor Metabolism of (Disorder)

Summary: the investigators team had found that the presence of dynamic changes of clopidogrel resistance are not associated with genetic factors. currently, study on moderate doses of statins and dynamic clopidogrel resistance has not been reported, therefore this study will observe 160 cases of open prospective secondary prevention in patients with cerebral infarction. excluded: those patients occurs clopidogrel resistance because of slow metabolism caused by cytochrome p450 isoenzyme 2c19（cyp2c19, and then observed the impact of the cytochrome p450 isoenzyme 3a4 （cyp3a4）-metabolized and non-cytochrome p450 isoenzyme 3a4 （cyp3a4）-metabolized statins dynamically on clopidogrel resistance in the next 9 months, adverse events will be recorded, the metabolite of clopidogrel（h4 ）and the polymorphism of cytochrome p450 isoenzyme 2c19 （cyp2c19）/cytochrome p450 isoenzyme 3a4 （cyp3a4）/ cytochrome p450 isoenzyme 2c9（cyp2c9）will be detected. expected result: the patients use the cytochrome p450 isoenzyme 3a4（cyp3a4）-metabolized statins will result in dynamic clopidogrel resistance easily ,h4 levels will decline, and clopidogrel resistance is not related to the polymorphism of cytochrome p450 isoenzyme 3a4 （cyp3a4）.


Eligibility criteria:
inclusion criteria: * the patient must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. * age \ 45 years ,male or female. * the patient have been cerebral infarction for one month. * national institutes of health stroke scale（nihss）score ≤23 points. * blood platelet count greater than 150×10\^9／l,and less than 500×10\^9／l. * the patient never do not taking aspirin 、dipyridamole、clopidogrel,or the patient had been taken these anti-platelet drugs but has been discontinued for two weeks at least. * the patient never do not taking statins or the patient have been stop taking statins 2 weeks for two weeks. exclusion criteria: * allergic constitution , or allergic to the composition of the drugs in this study. * national institutes of health stroke scale（nihss） score \>23 points. * atrial fibrillation and other cardiogenic cerebral embolism. * patients who were undergone surgery and trauma (including fractures) within the past three month. * patients with known dysfunction of vital organs or suffered from serious cardiovascular disease ，or coagulation disorders. * the patient took proton pump inhibitors recently. * the history of data collection and the follow-up process can not be saved.

Keywords: clopidogrel-drug interactions